Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment. (April 2017) - Sebert, M.; Bally, C.; Peterlin, P.; Beyne-Rauzy, O.; Legros, L.; Gourin, M.P.; Sanhes, L.; Wattel, E.; Gyan, E.; Park, S.; Stamatoullas, A.; Laribi, K.; et al.